USP <711> Dissolution Testing Automation Guide: Multi-Stage S1/S2/S3 Calculations in LIMS

Dissolution testing is one of the most critical release tests for solid oral dosage forms (tablets, capsules). Under United States Pharmacopeia (USP) <711> and Ph. Eur. 2.9.3, dissolution testing requires multi-stage acceptance criteria evaluation across Stage 1 (S1: 6 units), Stage 2 (S2: 6 additional units), and Stage 3 (S3: 12 additional units).

Calculating percentage dissolved (% drug release) across individual units, calculating mean percentage dissolved, correcting for sample volume replacement, and checking whether individual dosage units fall below (Q - 15%) or (Q - 25%) manually in Excel spreadsheets creates severe data integrity risks and 483 inspection audit findings.

Novaqis LIMS provides purpose-built USP <711> mathematical testing worksheets: • Automated Stage Evaluation: If all 6 units in Stage 1 meet the criteria (each unit not less than Q + 5%), the test passes automatically. If any unit fails, the system automatically prompts Stage 2 (S1 + S2, total 12 units) with updated criteria (mean ≥ Q and no unit < Q - 15%). • Double-Blind Data Entry Verification: Enforces second-analyst verification or automated UV/HPLC chromatography data ingestion via IDAS IoT middleware. • Automated Volume Correction Factors: Pre-configured mathematical formulas account for media withdrawal and replacement volumes during multi-timepoint profile testing.

When a dissolution test fails Stage 3 criteria, Novaqis LIMS immediately triggers an automated Phase 1 Laboratory OOS Investigation checklist (checking media preparation, deaeration, vessel centering, paddle/basket wobble, and chromatographic analysis) to isolate analytical errors before initiating Phase 2 manufacturing investigations.